ecrin-mdr-crcClinical2005AdenocarcinomaColorectal CancerMetastasesAdenocarcinomaColorectal CancerMetastasesInterventionalhttps://newmdr.ecrin.org/Study/2012161United States1Metastatic Colorectal AdenocarcinomaAnti TAG-72Monoclonal AntibodyECRIN MDRTerminatedfalseSafety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal AdenocarcinomaThis is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal cancer. The objectives of the study are to obtain information on the safety of radiolabeled IDEC-159, as well as its activity in colorectal cancer. Another objective is to determine the maximum tolerated dose (MTD). The study duration is 2 years with visits occuring daily and/or weekly for the first 3 months, and every 6 weeks until the end of the 2 year period.2005-01-152012161NCT00102024